A Phase 3 interventional study of LB1148 and Placebo in Ileus and Gastro-Intestinal Disorder, sponsored by Palisade Bio. Terminated at 23 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by Palisade Bio · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Ileus with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Ileus · United States.
Among the 59 studies in Ileus with a site in United States, this one is the 45th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 3, and was the 54th registered.
167 studies on the registry are indexed under Ileus; 23 are open to participants now.
Browse Ileus studies →4 of the 59 studies in Ileus with a site in United States are open now. Recruiting first, the newest first:
Casey Morehouse, DO · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
Stefan Holubar MD MS FACS, FASCRS · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Ileus studies recruiting now, 12 (63%) set no upper age limit and 4 (21%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 12 · Phase 4 7
First in 2001; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 90 across 138 interventional studies indexed under Ileus.
Median enrollment 80 across the 53 interventional studies, 150 across the 6 observational. Of the 48 that completed or were terminated, 22 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 59 have an industry lead sponsor. The 10 most frequent:
Palisade Bio is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Palisade Bio has 2 studies filed under Ileus — fewer than ten, so there is no comparison to draw.
2 of the studies in Ileus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05344417Ohio State UniversityLow Pressure Pneumoperitoneum and Postoperative Ileus | 2026-12-30 |
| NCT07574437The Cleveland ClinicAt-Home Bowel Stimulation | 2027-07-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Ileus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.
This will be a multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of LB1148 in return to bowel function for subjects undergoing planned bowel resection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will be eligible for participation in the study only if they meet ALL of the following inclusion criteria:
Exclusion Criteria:
Subjects will not be eligible for participation in the study if they meet ANY of the following exclusion criteria:
Has or potential risk factors to taking TXA. These include subjects with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LB1148
Drug: Placebo
Drug pages: Tranexamic Acid · Protease Inhibitor Formulation LB1148
A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Also known as: Active
A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Time to Return of Gastrointestinal Function
The later of the times in hours from placement of the last skin staple or suture to the time of toleration of solid food (defined as the time a subject finished a meal that required chewing and experienced no significant nausea/vomiting for 4 hours after the solid meal) and the first bowel movement, up to 14 days post-surgery
Time frame: From surgical procedure up to 14 days in hospital
Time to First Bowel Movement
Time in hours from placement of the last skin staple or suture to the time of first bowel movement
Time frame: From surgical procedure up to 14 days in hospital
Time Subject is Ready for Discharge
Time subject is ready for discharge, defined as the time from the end of surgery to the time the subject is ready for hospital discharge solely based on the recovery of GI function, as determined by the surgeon
Time frame: From surgical procedure up to 14 days in hospital
Time Discharge Order Written
Time discharge order written, defined as the time from the end of surgery to the time that the hospital discharge order is written
Time frame: From surgical procedure up to 14 days in hospital
Time of Actual Discharge
Time of actual discharge, defined as the time from the end of surgery to the time the subject is actually discharged from the hospital
Time frame: From surgical procedure up to 14 days in hospital
| Milestone | LB1148 | Placebo |
|---|---|---|
| Started | 13 | 10 |
| Completed | 13 | 7 |
| Not completed | 0 | 3 |
| Withdrew: Protocol violation | 0 | 3 |
The later of the times in hours from placement of the last skin staple or suture to the time of toleration of solid food (defined as the time a subject finished a meal that required chewing and experienced no significant nausea/vomiting for 4 hours after the solid meal) and the first bowel movement, up to 14 days post-surgery
| hours | LB1148 | Placebo |
|---|---|---|
| Time to Return of Gastrointestinal Function | 81.7 ± 44.67 | 90.57 ± 76.25 |
Time in hours from placement of the last skin staple or suture to the time of first bowel movement
| hours | LB1148 | Placebo |
|---|---|---|
| Time to First Bowel Movement | 51.54 ± 31.08 | 46.67 ± 24.66 |
Time subject is ready for discharge, defined as the time from the end of surgery to the time the subject is ready for hospital discharge solely based on the recovery of GI function, as determined by the surgeon
| hours | LB1148 | Placebo |
|---|---|---|
| Time Subject is Ready for Discharge | 154.48 ± 102.09 | 113.11 ± 74.75 |
Time discharge order written, defined as the time from the end of surgery to the time that the hospital discharge order is written
| hours | LB1148 | Placebo |
|---|---|---|
| Time Discharge Order Written | 155.62 ± 100.63 | 113.11 ± 74.75 |
Time of actual discharge, defined as the time from the end of surgery to the time the subject is actually discharged from the hospital
| hours | LB1148 | Placebo |
|---|---|---|
| Time of Actual Discharge | 159.01 ± 100.33 | 116.81 ± 75.30 |
Collected over All AEs were collected for all subjects during their participation from Study Day 1 through Hospital Discharge or Day 16, whichever is earlier.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LB1148 | 0/13 (0%) | 7/13 (53.8%) | 13/13 (100%) |
| Placebo | 0/10 (0%) | 4/10 (40%) | 7/10 (70%) |
| Event | LB1148 | Placebo |
|---|---|---|
| Postoperative IleusInjury, poisoning and procedural complications | 3/13 | 1/10 |
| Anastomatic leakInjury, poisoning and procedural complications | 0/13 | 1/10 |
| SepsisInjury, poisoning and procedural complications | 0/13 | 1/10 |
| Respiratory AcidosisRespiratory, thoracic and mediastinal disorders | 0/13 | 1/10 |
| Abdominal AbscessInjury, poisoning and procedural complications | 1/13 | 0/10 |
| Gastrointestinal stoma necrosisInjury, poisoning and procedural complications | 1/13 | 0/10 |
| Pelvic AbscessInjury, poisoning and procedural complications | 1/13 | 0/10 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/13 | 0/10 |
| Event | LB1148 | Placebo |
|---|---|---|
| BradycardiaCardiac disorders | 2/13 | 4/10 |
| Procedural HypotensionInjury, poisoning and procedural complications | 5/13 | 4/10 |
| TachycardiaCardiac disorders | 4/13 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 2/13 | 2/10 |
| Procedural hypertensionInjury, poisoning and procedural complications | 2/13 | 2/10 |
| HypertensionVascular disorders | 1/13 | 2/10 |
| Postoperative ileusInjury, poisoning and procedural complications | 2/13 | 0/10 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/13 | 0/10 |
| HypocalcaemiaMetabolism and nutrition disorders | 2/13 | 0/10 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/13 | 0/10 |
| Age, Categorical(Participants) | LB1148 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 7 | 19 |
| >=65 years | 1 | 3 | 4 |
| Age, Continuous(years) | LB1148 | Placebo | Total |
|---|---|---|---|
| Mean | 45.2 ± 12.59 | 54.0 ± 17.47 | 49.0 ± 15.21 |
| Sex: Female, Male(Participants) | LB1148 | Placebo | Total |
|---|---|---|---|
| Female | 4 | 5 | 9 |
| Male | 9 | 5 | 14 |
| Race (NIH/OMB)(Participants) | LB1148 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 10 | 10 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | LB1148 | Placebo | Total |
|---|---|---|---|
| United States | 13 | 10 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Mar 2023, 8 months.
Results were first posted in Jun 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tranexamic Acid · Protease Inhibitor Formulation LB1148
Palisade Bio